Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial

<div>(a) HIV-1 RNA suppression on DRV/r-based second-line treatment, by dose. Patients with HIV-1 subtype B virus. (b) HIV-1 RNA suppression on DRV/r-based second-line treatment, by dose. Patients with HIV-1 subtype non-B virus.</div>

AIDS Research and Treatment

fig1

Figure 1

Figure 1: Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial 